Zacks Research Brokers Boost Earnings Estimates for Omnicell, Inc. (NASDAQ:OMCL)

Omnicell, Inc. (NASDAQ:OMCL) – Equities research analysts at Zacks Research increased their Q3 2024 earnings per share estimates for Omnicell in a research note issued to investors on Tuesday, September 10th. Zacks Research analyst U. Biswas now forecasts that the company will earn $0.17 per share for the quarter, up from their prior estimate of $0.16. The consensus estimate for Omnicell’s current full-year earnings is $0.64 per share. Zacks Research also issued estimates for Omnicell’s Q4 2024 earnings at $0.17 EPS, FY2024 earnings at $0.55 EPS, Q1 2025 earnings at $0.13 EPS, Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.12 EPS and FY2025 earnings at $0.49 EPS.

A number of other equities research analysts have also recently commented on OMCL. JPMorgan Chase & Co. raised their target price on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research report on Friday, August 23rd. StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a research report on Wednesday. Benchmark reiterated a “buy” rating and set a $38.00 target price on shares of Omnicell in a research report on Monday, July 15th. Bank of America boosted their price target on shares of Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Finally, Wells Fargo & Company increased their price objective on shares of Omnicell from $26.00 to $30.00 and gave the company an “equal weight” rating in a report on Friday, August 2nd. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.83.

Omnicell Trading Down 0.4 %

Shares of NASDAQ:OMCL opened at $43.07 on Thursday. The company has a current ratio of 2.45, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47. Omnicell has a 12-month low of $25.12 and a 12-month high of $56.06. The business has a 50 day moving average of $36.77 and a two-hundred day moving average of $31.45. The company has a market capitalization of $1.98 billion, a PE ratio of -93.63, a PEG ratio of 50.19 and a beta of 0.83.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. The company had revenue of $276.80 million during the quarter, compared to the consensus estimate of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The firm’s quarterly revenue was down 7.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.29 earnings per share.

Hedge Funds Weigh In On Omnicell

Institutional investors and hedge funds have recently bought and sold shares of the business. Nisa Investment Advisors LLC lifted its stake in Omnicell by 248.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after purchasing an additional 1,000 shares in the last quarter. EntryPoint Capital LLC increased its holdings in shares of Omnicell by 121.2% in the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after purchasing an additional 1,345 shares during the last quarter. CWM LLC increased its holdings in shares of Omnicell by 68.2% in the second quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after purchasing an additional 1,236 shares during the last quarter. Benjamin Edwards Inc. lifted its position in Omnicell by 36.4% during the first quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after buying an additional 868 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new position in Omnicell during the second quarter worth $104,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.